Yield10 Bioscience Announces Successful Evaluation of Emergence and Establishment in Field Tests of Winter Camelina Varieties...
August 04 2020 - 8:30AM
Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience
company, today announced that it conducted field testing during the
2019/2020 winter season to evaluate emergence of winter Camelina
sativa varieties. Yield10 is developing double haploid lines as a
foundation for Camelina development and breeding for crossing in
new performance traits. The testing of these winter varieties
is part of Yield10’s development of Camelina sativa in the medium
term for use at commercial scale as a cash cover crop for North
America. Cover crops are becoming increasingly important to improve
the sustainability of food production and maybe an ideal way for
farmers to open up large areas for new crops producing novel
products by complementing and not competing for acres with major
food and feed crops while increasing farm revenue.
Two wild-type and two double haploid winter Camelina lines
developed in-house by Yield10’s Canadian subsidiary, Metabolix
Oilseeds, were studied in the field test. The winter Camelina
plantings were conducted in August and September 2019 in
Saskatchewan, Canada. Emergence of the seedlings after planting was
in the range of 70-80% and 90-100%, respectively, depending on the
date of planting. The field test site was snow covered from late
October 2019 to mid-April 2020, and optimal spring emergence of the
Camelina lines was observed in May 2020. Harvest of seed is
expected in the third quarter of 2020 and seed generated in the
study will be available for further planting and evaluation.
“Our team has developed new double haploid winter Camelina
varieties which performed very well in our winter field trial under
the extreme winter conditions encountered in Saskatchewan,” said
Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience.
“As development of our novel performance traits progresses, we
envision deploying our traits in double haploid varieties of both
winter and spring Camelina. Having this germplasm foundation will
enable us to combine our proprietary traits in both Camelina
varieties, expanding acreage potential for the crop. Double haploid
Camelina lines have more uniform, stable performance, which is an
important attribute for growers of commercial crops.”
About Yield10
Bioscience
Yield10 Bioscience, Inc. is an agricultural bioscience company
developing crop innovations to improve crop yields and enhance
sustainable global food security. The Company utilizes its
proprietary “GRAIN“ (Gene Ranking Artificial Intelligence Network)
gene discovery platform to identify gene targets to improve yield
performance and value in major commercial food and feed crops.
Yield10 uses its Camelina oilseed platform to rapidly evaluate and
field test new trait leads enabling the translation of promising
new traits into the major commercial crops. As a path toward
commercialization, Yield10 is pursuing a partnering approach with
agricultural companies to drive new traits into development in
crops such as canola, soybean and corn. The Company is also
developing Camelina as a platform crop for producing nutritional
oils and specialty products such as PHA biomaterials for use in
water treatment and bioplastics. Yield10 is headquartered in
Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon,
Canada.
For more information about the company, please visit
www.yield10bio.com, or follow the Company on Twitter, Facebook and
LinkedIn.
(YTEN-G)
Safe Harbor for Forward-Looking
Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, statements regarding the Company’s intentions with
regard to development of Camelina sativa for use at commercial
scale as a cover crop for North America, the use of cover crops as
a way to open up large areas for new crops producing novel products
by complementing and not competing for acres with major food and
feed crops while increasing farm revenue, plans to complete field
tests with winter Camelina in 2020, the results and outcome of, and
information gathered from, those tests, the ability to generate
value from Camelina oil and meal, including but not limited to the
ability to use the results of the tests in future studies or
licensing, collaboration or other commercial activities, and
whether the company’s traits will increase seed yield or boost oil
content, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including the risks and uncertainties
detailed in Yield10 Bioscience's filings with the Securities and
Exchange Commission. Yield10 assumes no obligation to update any
forward-looking information contained in this press release or with
respect to the matters described herein.
Contacts:
Yield10 Bioscience:
Lynne H. Brum, (617) 682-4693, LBrum@yield10bio.com
Investor Relations: Bret Shapiro, (561) 479-8566,
brets@coreir.comManaging Director, CORE IR
Media Inquiries: Eric Fischgrund, eric@fischtankpr.com FischTank
PR
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/6d825b85-4185-4701-8495-19ec20c8d752
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Apr 2023 to Apr 2024